← Back to Search

Vasodilator

2 for Raynaud's Disease

Phase 3
Waitlist Available
Research Sponsored by MediQuest Therapeutics
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up three months
Awards & highlights

Study Summary

The purpose of this research study is to test the safety, tolerability, and effectiveness of Topical AmphiMatrix with Nitroglycerin (MQX0503) to relieve Raynaud's symptoms and increase blood flow to the fingers.

Eligible Conditions
  • Raynaud's Disease

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~three months
This trial's timeline: 3 weeks for screening, Varies for treatment, and three months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Reduction in Raynaud's Condition Score
Secondary outcome measures
Frequency and severity of adverse events.

Side effects data

From 2019 Phase 4 trial • 66 Patients • NCT02209636
38%
Non-serious adverse events
3%
Hospitalization
100%
80%
60%
40%
20%
0%
Study treatment Arm
Lanthanum Carbonate
Placebo
Placebo- Phosphorus Balance Sub-study
Lanthanum Carbonate- Phosphorus Balance Sub-study

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: 2Experimental Treatment1 Intervention
Placebo - Topical AmphiMatrix
Group II: 1Active Control1 Intervention
Topical AmphiMatrix with Nitroglycerin

Find a Location

Who is running the clinical trial?

MediQuest TherapeuticsLead Sponsor
10 Previous Clinical Trials
622 Total Patients Enrolled
Jan Ohrstrom, PhDStudy DirectorMediQuest Therapeutics

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
A Study of a Topical Form of Nitroglycerin and Placebo in the Treatment and Prevention of Raynaud's Phenomenon
2007. "A Study of a Topical Form of Nitroglycerin and Placebo in the Treatment and Prevention of Raynaud's Phenomenon". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00577304.
All > Prevention
~12 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top